KYMR vs MRK · rev $99.4M vs P/E 33, rev $16.61B
Kymera Therapeutics Inc (KYMR) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported KYMR revenue for 2026-06-30 was $99.4M. Net income was -$130.4M. KYMR currently screens at market cap $7.39B.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
KYMR currently screens at market cap $7.39B. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the KYMR and MRK stock pages for the full models.
Not investment advice.